Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The sickle-induced cation leak pathway, commonly referred to as "Psickle", is a deoxygenation-induced, non-selective cation conductance found in the red blood cells of individuals with sickle cell disease (Lew & Bookchin, 2005). Upon deoxygenation, the polymerization of hemoglobin S (HbS) causes mechanical stress on the erythrocyte membrane, activating this pathway and allowing the influx of calcium and sodium and the efflux of potassium (Tiffert et al., 2003). The resulting increase in intracellular calcium activates the Gardos channel (KCNN4), leading to rapid loss of potassium and water, which causes cell dehydration, increases HbS concentration, and accelerates further sickling (Vandorpe et al., 2011). This pathway is a critical therapeutic target because its inhibition can prevent the cycle of dehydration and sickling that leads to vaso-occlusive crises and hemolysis. Recent evidence suggests that the mechanosensitive ion channel Piezo1 may be a primary molecular component of the Psickle conductance (Cahalan et al., 2015). Pharmacological interventions, such as the Gardos channel inhibitor Senicapoc or experimental Piezo1 inhibitors like GsMTx4, aim to block this leak or its downstream effects to maintain red cell hydration and reduce the severity of sickle cell disease symptoms (Ataga et al., 2008).
Inhibition of deoxygenation-induced cation permeability to prevent erythrocyte dehydration and subsequent hemoglobin S polymerization.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sickle-induced non-selective cation pathway (Psickle) (Psickle).